Discover
SMMT
Summit Therapeutics Inc.
13.96
1 x 13.80
1 x 14.20
bid
ask
+
0.42
3.10%
400 @ 04:00 PM
14.00 +0.04 (0.29%)
| Ytd | -20.18% | |
| 1y | -50.27% |
13.52
day range
14.02
12.55
52 week range
28.66
| Open | 13.90 | Prev Close | 13.54 | Low | 13.52 | High | 14.02 | Mkt Cap | 11.14B |
| Vol | 2.12M | Avg Vol | 5.07M | EPS | -1.60 | P/E | -8.72 | Forward P/E | 3.72 |
| Beta | -1.26 | Short Ratio | 5.46 | Inst. Own | 15.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 14.68 | 200-d Avg | 17.01 | 1yr Est | 28.81 |
| Income Statement | |||
| Operating Expenses | 220.50M | ||
| Research and Development Expense | 157.73M | ||
| Selling, General and Administrative Expense | 62.76M | ||
| Operating Income | -220.50M | ||
| Net Income | -215.70M | ||
| Net Income Common Stock | -215.70M | ||
| Net Income Common Stock (USD) | -215.70M | ||
| Consolidated Income | -215.70M | ||
| Earnings per Basic Share | 0.00 | ||
| Earnings per Basic Share (USD) | 0.00 | ||
| Earnings per Diluted Share | 0.00 | ||
| Earning Before Interest & Taxes (EBIT) | -215.70M | ||
| Earning Before Interest & Taxes (USD) | -215.70M | ||
| Weighted Average Shares | 778.18M | ||
| Weighted Average Shares Diluted | 778.18M | ||
| Balance Sheet | |||
| Cash and Equivalents | 419.68M | ||
| Cash and Equivalents (USD) | 419.68M | ||
| Investments | 271.31M | ||
| Investments Current | 271.31M | ||
| Current Assets | 720.58M | ||
| Property, Plant & Equipment Net | 21.19M | ||
| Total Assets | 752.19M | ||
| Debt Current | 3.55M | ||
| Total Debt | 20.38M | ||
| Current Liabilities | 103.57M | ||
| Debt Non-Current | 16.83M | ||
| Total Liabilities | 122.20M | ||
| Accumulated Retained Earnings (Deficit) | -2.70B | ||
| Accumulated Other Comprehensive Income | -2.66M | ||
| Shareholders Equity | 629.98M | ||
| Shareholders Equity (USD) | 629.98M | ||
| Assets Non-Current | 31.61M | ||
| Total Debt (USD) | 20.38M | ||
| Goodwill and Intangible Assets | 1.97M | ||
| Liabilities Non-Current | 18.64M | ||
| Trade and Non-Trade Payables | 22.90M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 46.00K | ||
| Net Cash Flow from Financing | 231.08M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 312.85M | ||
| Capital Expenditure | -909.00K | ||
| Issuance (Purchase) of Equity Shares | 231.08M | ||
| Net Cash Flow from Investing | 222.90M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 223.81M | ||
| Net Cash Flow from Operations | -141.12M | ||
| Effect of Exchange Rate Changes on Cash | 1000 | ||
| Share Based Compensation | 68.71M | ||